Collegium Pharmaceutical (NASDAQ:COLL) EVP Scott Dreyer Sells 49,976 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 49,976 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the transaction, the executive vice president owned 71,770 shares of the company’s stock, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Scott Dreyer also recently made the following trade(s):

• On Monday, December 8th, Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00.

Collegium Pharmaceutical Trading Down 1.0%

Shares of NASDAQ:COLL traded down $0.38 during mid-day trading on Friday, reaching $36.90. 102,826 shares of the company were exchanged, compared to its average volume of 444,218. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $50.79. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48. The firm’s 50-day simple moving average is $45.74 and its 200 day simple moving average is $42.09. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 21.58 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. During the same quarter in the prior year, the business earned $1.77 earnings per share. The company’s quarterly revenue was up 12.9% on a year-over-year basis. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Collegium Pharmaceutical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after acquiring an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares during the last quarter. Jane Street Group LLC grew its position in shares of Collegium Pharmaceutical by 218.7% during the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after acquiring an additional 90,255 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 1,153 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a report on Tuesday, February 10th. HC Wainwright restated a “buy” rating and set a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Finally, Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.